

# New Rule Consent Criteria

<b>Consent process (all criteria must be met):</b>		<b>45 CFR §46.116 and 21 CFR 50.20</b>
<input type="checkbox"/>	1) The consent process will be legally effective	
<input type="checkbox"/>	2) Circumstances provide the prospective subject or LAR sufficient opportunity to consider whether to participate	
<input type="checkbox"/>	3) Circumstances minimize the possibility of coercion or undue influence	
<input type="checkbox"/>	4) The information will be provided be in language understandable to the subject or LAR	
<input type="checkbox"/>	5) The consent contains information that a reasonable person would want to have in order to make an informed decision about whether to participate	
<input type="checkbox"/>	6) The consent begins with the key information why one might or might not want to participate in the research	
<input type="checkbox"/>	7) There is no exculpatory language Exculpatory language is language through which the subject or LAR is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution or its agents from liability for negligence	
<input type="checkbox"/>	8) The required and appropriate additional elements of consent will be disclosed	

<b>Required Elements of consent (all must be met):</b>		<b>45 CFR §46.116 and 21 CFR §50.25</b>
<input type="checkbox"/>	Study involves research	
<input type="checkbox"/>	Purposes of the research	
<input type="checkbox"/>	Expected duration of the subject's participation	
<input type="checkbox"/>	Procedures to be followed	
<input type="checkbox"/>	Identification of any procedures which are experimental	
<input type="checkbox"/>	Any reasonably foreseeable risks or discomforts	
<input type="checkbox"/>	Any benefits to the subject or to others which may reasonably be expected from the research	
<input type="checkbox"/>	Any appropriate alternative procedures or courses of treatment that might be advantageous	

# New Rule Consent Criteria

Required Elements of consent (all must be met):		45 CFR §46.116 and 21 CFR §50.25
<input type="checkbox"/>	The extent, if any, to which confidentiality of records identifying the subject will be maintained When appropriate, disclose any limits on confidentiality imposed by mandatory reporting and any possibility of loss of confidentiality due to media attention	
	How to contact the investigator for <ul style="list-style-type: none"> <li><input type="checkbox"/> • questions</li> <li><input type="checkbox"/> • concerns</li> <li><input type="checkbox"/> • complaints</li> </ul>	
	How to contact someone independent of the investigator for: <ul style="list-style-type: none"> <li><input type="checkbox"/> • questions</li> <li><input type="checkbox"/> • concerns</li> <li><input type="checkbox"/> • complaints</li> <li><input type="checkbox"/> • subjects rights</li> </ul>	
<input type="checkbox"/>	Whom to contact in the event of a research-related injury	
<input type="checkbox"/>	Participation is voluntary	
<input type="checkbox"/>	Refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled	
<input type="checkbox"/>	The subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.	
<input type="checkbox"/>	<p>One of the following statements about any identifiable private information or identifiable biospecimens:</p> <p>(i) A statement that identifiers might be removed from the identifiable private information or identifiable biospecimens and that, after such removal, the information or biospecimens could be used for future research studies or distributed to another investigator for future research studies without additional informed consent from the subject or the legally authorized representative</p> <p><b>or</b></p> <p>(ii) A statement that the subject's information or biospecimens collected as part of the research, even if identifiers are removed, will not be used or distributed for future research studies.</p>	

# New Rule Consent Criteria

Additional elements of consent, required when appropriate		45 CFR §46.111 and 21 CFR §50.25
<input type="checkbox"/>	The research may involve risks to the subject which are currently unforeseeable	
<input type="checkbox"/>	The research may involve risks to the embryo or fetus, if the subject is or may become pregnant, which are currently unforeseeable	
<input type="checkbox"/>	Anticipated circumstances under which the subject's participation may be stopped without the subject's consent	
<input type="checkbox"/>	Any additional costs to the subject that may result from participation in the research	
<input type="checkbox"/>	The consequences of a subject's decision to withdraw from the research	
<input type="checkbox"/>	Procedures for orderly termination of participation by the subject	
<input type="checkbox"/>	New findings that may relate to the subject's willingness to continue participation will be provided to the subject	
<input type="checkbox"/>	The approximate number of subjects involved in the study Amount and timing of all payments	
<input type="checkbox"/>	A statement that the subject's biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subject will or will not share in this commercial profit	
<input type="checkbox"/>	A statement regarding whether clinically relevant research results, including individual research results, will be disclosed to subjects, and if so, under what conditions	
<input type="checkbox"/>	whether the research will or might include whole genome sequencing	
<input type="checkbox"/>	Amount and timing of all payments	

Consent Requirements for research involving more than <Minimal Risk> to subjects		45 CFR §46.111 and 21 CFR §50.25
<input type="checkbox"/>	Whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained	
<input type="checkbox"/>	Whether any compensation is available if injury occurs and, if so, what they consist of, or where further information may be obtained	

# New Rule Consent Criteria

Consent Requirements for FDA-regulated research (all must be met):		21 CFR §50.25
<input type="checkbox"/>	Statement that FDA may inspect the records	
<input type="checkbox"/>	The consent document does not give the subject the option of having data removed When a subject withdraws from a study, the data collected on the subject to the point of withdrawal remains part of the study database and may not be removed (Guidance for Sponsors, Clinical Investigators, and IRB Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials)	
<input type="checkbox"/>	For controlled drug/device trials (except Phase I drug trials) and pediatric device surveillance trials: "A description of this clinical trial will be available on <a href="http://www.ClinicalTrials.gov">http://www.ClinicalTrials.gov</a> , as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time."	

Consent Requirements for research subject to ICH-GCP 4.8.5 and 4.8.10	
<input type="checkbox"/>	A description of the IRB and its role
<input type="checkbox"/>	The probability for random assignment, if any
<input type="checkbox"/>	Any subject responsibilities
<input type="checkbox"/>	The reasonably foreseeable risks to an embryo, fetus, or nursing infant, if any
<input type="checkbox"/>	When there is no intended clinical benefit to the subject, a statement to that effect
<input type="checkbox"/>	Statement that the monitors, auditors, IRB, and regulatory authorities will be granted direct access to the subject's original medical records for verification of clinical trial procedures and data, without violating the confidentiality of the subject, to the extent permitted by the applicable laws and regulations and that, by signing a written informed consent document, the subject or the subject's legally acceptable representative is authorizing such access.
<input type="checkbox"/>	Statement that if the results of the trial are published, the subject's identity will remain confidential

# New Rule Consent Criteria

## Required when research involves a submission of genomic data to the NIH database of Genotypes and Phenotypes (dbGaP)

[Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (GWAS)]

### The IRB must determine all the following requirements are met:

<input type="checkbox"/>	The submission of data to the NIH GWAS data repository and subsequent sharing for research purposes are consistent with the informed consent of study participants from whom the data were obtained
<input type="checkbox"/>	The IRB has considered the risks to individuals, their families, and groups or populations associated with data submitted to the NIH GWAS data repository
<input type="checkbox"/>	The genotype and phenotype data to be submitted were collected in a manner consistent with 45 CFR §46
<input type="checkbox"/>	The identities of data subjects cannot be readily ascertained or otherwise associated with the data by the repository staff or secondary data
<input type="checkbox"/>	The 18 identifiers enumerated at section 45 CFR §164.514(b)(2) (the HIPAA Privacy Rule) are removed
<input type="checkbox"/>	The submitting institution has no actual knowledge that the remaining information could be used alone or in combination with other information to identify subjects

### Consent documentation Requirements

45 CFR §46.117, 21 CFR §50.27, and ICH-GCP 4.8.8

<input type="checkbox"/>	The document is accurate and complete
<input type="checkbox"/>	The document embodies the required and appropriate additional elements of consent
<input type="checkbox"/>	The document will be signed and dated by the subject or LAR and by the person obtaining consent
<input type="checkbox"/>	The key information will be presented to the subject before other information
<input type="checkbox"/>	A signed and dated copy will be given to the person signing the form**
<input type="checkbox"/>	The investigator will give the subject or LAR adequate opportunity to read it before it is signed and dated
<input type="checkbox"/>	For clinical research: If the subject cannot read, an <Impartial Witness> will witness the consent process and sign and date the form
<input type="checkbox"/>	Signature blanks are appropriate for the protocol and correctly labeled
<input type="checkbox"/>	Addendum consents are identified as such